Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

5 August 2016

Microbion’s MBN-101 receive Fast Track designation

Microbion Corporation (“Microbion”) of Bozeman, MT, USA and Microbion Pharma Corp. of Vancouver, BC, Canada, specializing in the treatment of hard to treat and antibiotic-resistant infections, announced that the U.S. FDA has granted MBN-101 Fast Track designation for adjunctive treatment of mild and moderate diabetic foot ulcer infections.
- Read more about Dr Reddy’s completes acquisition of eight products from Teva
Dr Reddy’s Laboratories has successfully completed the previously announced acquisition of eight Abbreviated New Drug Applications (ANDAs) in the US from Teva Pharmaceutical Industries and an affiliate of Allergan plc.
- Read more about NPPA revised ceiling price of 24 formulations and retail price of 31 formulations
NPPA has revised ceiling price of 24 formulations and retail price of 31 formulations which includes from anticancer, antidiabetic, antiviral, antibacterial, antifungal etc portfolios.

[adsense:336x280:8701650588]
- Read more about GSK & Google's Verily to develop bioelectronic medicines
GSK agreement with Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, to form Galvani Bioelectronics to enable the research, development and commercialisation of bioelectronic medicines. GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.
- Read more about Allergan divests global generic drugs business to Teva Pharma
Allergan plc announced that it has completed the divestiture of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd. Allergan has received $33.4 billion in cash and 100.3 million shares of Teva stock valued at $5.4 billion based on the opening price of $53.39 for Teva Pharmaceutical Industries Ltd. shares on August 2, 2016. These shares are subject to a twelve month holding period post-close of the transaction.
- Read more about Luminex Corporation Receives FDA Clearance for New ARIES® Flu A/B & RSV Test
Luminex Corporation announced that it has received FDA clearance for the ARIES® Flu A/B & RSV Assay. This is the second assay the FDA has cleared for use on the Luminex ARIES® System.
- Read more about Sorrento form Joint Venture with CHA Biotech to Develop and Commercialize Natural Killer Cell Therapies
Sorrento Therapeutics, Inc. an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced that it has entered into a binding term sheet to create a joint venture ("JV") with CHA Biotech Co. , LTD, of South Korea to develop and commercialize proprietary Chimeric Antigen Receptor ("CAR") modified cellular therapies based on CBT's Activated Killer Cell ("AKC") technology and five of Sorrento's CARs for all disease conditions, including oncology and infectious diseases. The JV covers products on a global basis with the exception of the Greater Chinese market.
- Read more about Sun Pharma receives US FDA approval for generic Glumetza
Sun Pharma has announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Glumetza, metformin hydrochloride extended release tablets 500 mg and 1000 mg.
- Read more about REGENXBIO's RGX-121 Gene Therapy receive Rare Pediatric Disease Designation by FDA
REGENXBIO Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to RGX-121, REGENXBIO’s investigational gene therapy product candidate for the treatment of Mucopolysaccharidosis Type II (MPS II).
- Read more about Pluristem Receives Positive Feedback from FDA for Phase III Trial of PLX-PAD in CLI
Pluristem Therapeutics Inc.announced that it has received positive feedback from the U.S. Food and Drug Administration (FDA) on the proposed Phase III trial of its PLX-PAD cells in the treatment of critical limb ischemia (CLI). This Phase III trial is intended to support a biologics license application (BLA).